IP Library Granted Patent US 10,549,037
Granted Patent B2
US 10,549,037 · App. 15/462,334 · Granted Feb 4, 2020

Glucagon administration system and methods

Inventor: Mark C. Estes (Malibu, CA)
Assignee: Bigfoot Biomedical, Inc.
A61M5/1723A61K38/26A61M5/003A61M5/14244A61M5/14248A61M5/24A61M2202/0486A61M2205/3561A61M2205/3584A61M2205/3592A61M2205/50A61M2205/502A61M2205/52A61M2205/8206A61M2230/201
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,549,037
App. No.
15/462,334
Granted
Feb 4, 2020
Kind
B2
Abstract

Some embodiments a glucagon administration system can provide a suggested glucagon dosage based on one or more particular parameters (e.g., the user's recent blood glucose characteristics, a glucagon sensitivity value of the user, and other parameters). In some circumstances, the glucagon administration system can receive information indicative of the user's blood glucose level and suggest a glucagon dosage that is at least partially dependent upon a previously stored glucagon sensitivity for the user.

Claims (33)

1. A medicine administration system, comprising:

a wearable glucose monitoring device;

a disposable and non-reusable insulin delivery device including:

an insulin cartridge comprising a plunger, a septum, and insulin;

a housing that retains the insulin cartridge; and

a drive system comprising a piston rod that is incrementally movable to apply a dispensing force to the plunger to dispense insulin through the septum;

a removable controller device including:

a controller housing that is removably attachable to the housing of the insulin delivery device;

a user interface comprising a display and one or more user-selectable buttons; and

a wireless communication device to receive glucose information from the wearable glucose monitoring device, the glucose information being indicative of a blood glucose level of the user,

wherein the removable controller device displays a suggested glucagon dosage in response to user input to the system, the suggested glucagon dosage being at least partially dependent upon a glucose sensitivity value, a target blood glucose level, and the blood glucose level of the user; and

a glucagon injector pen device or syringe that is separate from the disposable and non-reusable insulin delivery device and the controller device.

2. The system of claim 1 , wherein the controller device is configured to activate a glucagon dosage calculator that calculates the suggested glucagon dosage based at least in part on the glucose sensitivity value stored by the controller device, the target blood glucose level stored by the controller device, and the blood glucose level of the user.

3. The system of claim 1 , wherein the glucagon injector pen device or syringe is a glucagon injector pen in wireless communication with the removable controller device.

4. The system of claim 1 , further comprising:

a computer-readable program executed on a smart phone or tablet device, wherein the suggested glucagon dosage is calculated by the computer-readable program.

5. A medicine administration system, comprising:

a wearable glucose monitoring device;

a disposable and non-reusable insulin delivery device including:

an insulin cartridge comprising a plunger, a septum, and insulin;

a housing that retains the insulin cartridge; and

a drive system comprising a piston rod that is incrementally movable to apply a dispensing force to the plunger to dispense insulin through the septum;

a removable controller device including:

a controller housing that is removably attachable to the housing of the insulin delivery device;

a user interface comprising a display and one or more user-selectable buttons; and

a wireless communication device to receive glucose information from the wearable glucose monitoring device, the glucose information being indicative of a blood glucose level of the user; and

a glucagon dosage suggestion calculator that calculates a suggested glucagon dosage being at least partially dependent upon a glucose sensitivity value, a target blood glucose level, and the blood glucose level of the user; and

a glucagon injector pen device or syringe that is separate from the disposable and non-reusable insulin delivery device and the controller device.

6. The system of claim 5 , wherein the glucagon dosage suggestion calculator comprises a computer readable program executed on a smart phone or tablet device.

7. The system of claim 5 , wherein the glucagon dosage calculator is attached to the glucagon injector pen device or syringe.

8. The system of claim 5 , wherein the glucagon dosage suggestion calculator is configured to interact with the glucagon injector pen device or syringe.

9. The system of claim 5 , wherein the glucagon injector pen device or syringe is a glucagon injector pen in wireless communication with the removable controller device.

10. The system of claim 5 , wherein the disposable and non-reusable insulin delivery device is an insulin pump.

Assignments (21)
SECURITY INTEREST Recorded Jan 10, 2025
From: BIGFOOT BIOMEDICAL, INC.
To: MADRYN HEALTH PARTNERS, LP
Reel/Frame 069870/0456 →
RELEASE OF SECURITY INTEREST Recorded Jan 10, 2025
From: MADRYN FUND ADMINISTRATION, LLC
To: BIGFOOT BIOMEDICAL, INC.
Reel/Frame 069870/0588 →
SECURITY INTEREST Recorded Jan 10, 2025
From: MADRYN HEALTH PARTNERS, LP
To: MADRYN FUND ADMINISTRATION, LLC
Reel/Frame 069870/0519 →
SECURITY INTEREST Recorded Sep 30, 2024
From: MADRYN HEALTH PARTNERS, LP
To: MADRYN FUND ADMINISTRATION, LLC
Reel/Frame 069074/0001 →
SECURITY INTEREST Recorded Sep 30, 2024
From: BIGFOOT BIOMEDICAL, INC.
To: MADRYN HEALTH PARTNERS, LP
Reel/Frame 069073/0912 →
RELEASE OF SECURITY INTEREST Recorded Sep 30, 2024
From: MADRYN FUND ADMINISTRATION, LLC
To: BIGFOOT BIOMEDICAL, INC.
Reel/Frame 069071/0980 →
RELEASE OF SECURITY INTEREST Recorded Sep 24, 2024
From: MADRYN FUND ADMINISTRATION, LLC
To: BIGFOOT BIOMEDICAL, INC.
Reel/Frame 069030/0157 →
SECURITY INTEREST Recorded Sep 24, 2024
From: MADRYN HEALTH PARTNERS, LP
To: MADRYN FUND ADMINISTRATION, LLC
Reel/Frame 069030/0104 →
SECURITY INTEREST Recorded Sep 24, 2024
From: BIGFOOT BIOMEDICAL, INC.
To: MADRYN HEALTH PARTNERS, LP
Reel/Frame 069030/0296 →
SECURITY INTEREST Recorded Sep 23, 2024
From: MADRYN HEALTH PARTNERS, LP
To: MADRYN FUND ADMINISTRATION, LLC
Reel/Frame 069019/0188 →
SECURITY INTEREST Recorded Sep 23, 2024
From: BIGFOOT BIOMEDICAL, INC.
To: MADRYN HEALTH PARTNERS, LP
Reel/Frame 069019/0142 →
RELEASE OF SECURITY INTEREST Recorded Sep 23, 2024
From: MADRYN FUND ADMINISTRATION, LLC
To: BIGFOOT BIOMEDICAL, INC.
Reel/Frame 069019/0346 →
RELEASE OF SECURITY INTEREST Recorded Sep 12, 2024
From: MADRYN FUND ADMINISTRATION, LLC
To: BIGFOOT BIOMEDICAL, INC.
Reel/Frame 068948/0377 →
SECURITY INTEREST Recorded Sep 12, 2024
From: MADRYN HEALTH PARTNERS, LP
To: MADRYN FUND ADMINISTRATION, LLC
Reel/Frame 068948/0324 →
SECURITY INTEREST Recorded Sep 12, 2024
From: BIGFOOT BIOMEDICAL, INC.
To: MADRYN HEALTH PARTNERS, LP
Reel/Frame 068948/0172 →
RELEASE OF SECURITY INTEREST Recorded Sep 26, 2023
From: MADRYN FUND ADMINISTRATION, LLC
To: BIGFOOT BIOMEDICAL, INC.
Reel/Frame 065029/0271 →
SECURITY INTEREST Recorded Feb 10, 2023
From: MADRYN HEALTH PARTNERS, LP
To: MADRYN FUND ADMINISTRATION, LLC
Reel/Frame 062702/0145 →
SECURITY INTEREST Recorded Mar 12, 2021
From: BIGFOOT BIOMEDICAL, INC.
To: MADRYN HEALTH PARTNERS, LP
Reel/Frame 055583/0044 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 19, 2017
From: ASANTE SOLUTIONS, INC.
To: ASANTE LLC
Reel/Frame 042885/0536 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 19, 2017
From: ASANTE LLC
To: BIGFOOT BIOMEDICAL, INC.
Reel/Frame 042885/0583 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 19, 2017
From: ESTES, MARK C.
To: ASANTE SOLUTIONS, INC.
Reel/Frame 042743/0796 →
Continuity (2)
Continuation 14320863 · Jul 1, 2014
Related Publication 20170189615A1 · Jul 6, 2017